Skip to content
The Policy VaultThe Policy Vault

Nexavar (sorafenib) — Medica

Medullary thyroid carcinoma

Initial criteria

  • age ≥ 18 years
  • has tried at least one systemic therapy (e.g., Caprelsa, Cometriq, Retevmo, Gavreto)

Approval duration

1 year